AI in Drug Discovery and Development
Agenda
- Panel Introductions
- AI in Drug Discovery and Development
- “Fireside Chat” (panelist Q&A)
- Audience Q&A
Brian Repko (he/him)
- 11 years at Novartis (now retired)
- 8 years in oncology research
- 5 years in an internal CRO (-omic biomarkers)
- bulk RNA, DNA panel, scRNA, T/B cell, CITE-seq, spatial
- including validation and qualification
- Minneapolis-St Paul “chapter lead” for Bits-in-Bio
- R/Pharma and
{pharmaverse} contributor
![]()
![]()
![]()
Dr. Erika Kvikstad (she/her)
Geof Hannigan, PhD (he/him)
![]()
Director of Startup Engagement, Mayo Clinic
- Passionate about making a positive impact on patient lives by blending science, technology, and entrepreneurship
- Career spanning bench science, computational biology, business development, and startup engagement
- Co-founder and former Executive Director of Merck Digital Sciences Studio startup accelerator program
- Supporter of innovation ecosystems, including founding the Minnesota biotech networking group BiotechMN
- Blogging at Living Bio (https://livingbio.substack.com)
- Email: hannigan.geof@gmail.com
What is Drug Discovery and Development?
AI and DD&D - Brian (1/2)
- AI has always been a part of DD&D - comp.bio and comp.chem as fields
- New focus on GenAI, agentic workflows or skills, and improved tools
- Novartis efforts - data42, scientific vs operational AI, tooling
- Huge efforts to collect and connect preclinical, clinical trial, and real-world data
- Investments in predictive safety/tox, therapeutic design, and lab automation
- Data fit, quality, and integration are key to model success
- Unresolvable gaps in data - missing / mistaken / methods
- Existing knowledge is sometimes not reproducible or not accurate
- Hype is a bit out of control (Anthropic S-1) and DD&D is a miracle
- We are still learning basic biology and developing new methods (shRNA/sgRNA)
- Genuine effort on where to set the bar here
AI and DD&D - Brian (2/2)
- Drug Development / GXP
- CDISC efforts - 360i, USDM / TMF, SDTM-ADAM and data engineering coding
- Only non-critical tasks and then with auditing and approvals
- Validation of agents similar to that of R and R packages (with non-determinism)
- Regulatory Issues
- FDA already using AI for review of protocols and trial data (ELSA)
- Sponsors learning how to do the same on their side prior to submission
- What is successful use of AI in DD&D? What is ROI on the tools?
- Somewhat timelines (and perhaps cost) - biological latency still exists
- If we lower cost, does that change what we go after?
- Success as improving p(success) - better models, biomarkers, and trial designs
- If more drug candidates, do we create a bottleneck with patients? sites?
AI and DD&D - Erika (1/2)
We can build a better drug discovery process
AI and DD&D - Erika (2/2)
Two questions on the path to better medicines
AI and DD&D - Geof (1/2)
Leveraging AI Across the Pipeline
AI and DD&D - Geof (2/2)
AI Trends in Drug Discovery & Development